Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Paul Hudson
CEOPaul Hudson
Employees
84,587
Employees84,587
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
84,587
Employees84,587

SNY Key Statistics

Market cap
118.80B
Market cap118.80B
Price-Earnings ratio
11.96
Price-Earnings ratio11.96
Dividend yield
3.32%
Dividend yield3.32%
Average volume
3.88M
Average volume3.88M
High today
$49.16
High today$49.16
Low today
$47.70
Low today$47.70
Open price
$48.98
Open price$48.98
Volume
2.58M
Volume2.58M
52 Week high
$60.12
52 Week high$60.12
52 Week low
$44.62
52 Week low$44.62

SNY News

Simply Wall St 3h
Novavax Is Down 11.9% After Sanofi Takes Over EU Marketing of Nuvaxovid Vaccine

Sanofi announced it has completed the transfer of European Union marketing authorization for Novavax's COVID-19 vaccine, Nuvaxovid, taking on full commercial an...

Novavax Is Down 11.9% After Sanofi Takes Over EU Marketing of Nuvaxovid Vaccine
TipRanks 1d
Sanofi’s New Study on SAR446597: A Potential Game-Changer for Age-related Macular Degeneration

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock p...

Benzinga 3d
Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE). The patients...

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

More SNY News

TipRanks 3d
Sanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 101 from EUR 104 and keeps a Buy rating on the shares after updating the firm’s model ahead of...

Nasdaq 4d
Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment

(RTTNews) - Sanofi SA (SNY, SNYNF, SAN.PA) announced promising results from its ALPHAMEDIX-02 Phase 2 clinical trial evaluating AlphaMedix (212Pb-DOTAMTATE), a...

Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment
Seeking Alpha 4d
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU

Novavax (NASDAQ:NVAX) said that it has officially transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi (NASDAQ:SNY) within the...

Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU
TipRanks 4d
Novavax Transfers EU Vaccine Rights to Sanofi

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 4d
Novavax’s Nuvaxovid EU approval triggers $25M milestone payment from Sanofi

Novavax (NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), in the European Union enabling San...

Simply Wall St 6d
Revvity Is Up 11.9% After Announcing Sanofi Alliance to Expand Diabetes Diagnostics Portfolio

Revvity recently announced an alliance with Sanofi to expand its type 1 diabetes diagnostics portfolio, introducing a population-scale 4-plex in vitro diagnosti...

Revvity Is Up 11.9% After Announcing Sanofi Alliance to Expand Diabetes Diagnostics Portfolio
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.